Articles

Find an Article

Filter articles

Applied Filters

Showing 61 to 70 of 315 results

Medicine for the millions

Brazil01-06-2018Alice Rayol Sandes

Product development partnerships are likely to provide great opportunities for companies seeking to market biosimilar products in Brazil, where there is a huge reliance on public healthcare. Alice Rayol Sandes of Di Blasi, Parente & Associados has more.

Keeping trade fair

Mexico01-06-2018Hector Chagoya

As Mexico prepares for a presidential election in 2018, pharma IP owners are hoping that the progress made in trade negotiations is not undone. Hector Chagoya of Becerril Coca & Becerril reports.

Patent backlog in Brazil: slow, but welcome, progress

Brazil31-05-2018Kene Gallois and Ricardo Nunes

Brazil’s patent backlog has long caused concern for IP owners, particularly those in the pharmaceutical industry, but progress is being made, as Kene Gallois and Ricardo Nunes of Daniel Legal & IP Strategy report.

Eli Lilly: the trials and tribulations of antibody patents

17-04-2018

Courts have not always been able to appreciate the complexities around antibody patents, causing problems for innovation and investment, says Eli Lilly patent counsel Duane Marks in an interview with LSIPR.

AstraZeneca: no time for time-wasting

US08-03-2018

The IP team at AstraZeneca must “ruthlessly” prioritise how it spends time and resources, its vice president of global IP explained in an interview.

Getting into the biosimilars action

US06-03-2018Henk Heus and Ellen Sherin

The financial stakes in the biosimilars market are enormous, and an understanding of sequence IP for the underlying technologies and modes of action is key to entry into it, say Henk Heus and Ellen Sherin of GQ Life Sciences.

The licensing landscape at Pieris

US22-02-2018

Forming licensing agreements with other pharmaceutical companies is an important part of Pieris’s strategy, according to Ahmed Mousa, vice president of licensing, IP and legal affairs at the clinical-stage company.

Pfizer, patents and political quagmires

30-01-2018

Politics has a huge impact on enforcement in Africa, Asia and the Middle East, a senior corporate counsel at Pfizer has told LSIPR in an interview.

From London to Amsterdam: what the EMA’s move means for medicines regulation

EU15-12-2017Rachel Bradley

While the impact of the European Medicines Agency’s relocation from London to Amsterdam is unknown, industry and government will try to ensure that the UK remains at the forefront of medicines regulation, says Rachel Bradley of Penningtons Manches.

LSIPR 50 2017: Carl Gordon—Realising great ideas

US10-11-2017

Major tasks for Carl Gordon of OrbiMed, a healthcare fund, include drug pricing and helping to turn promising ideas into reality, as he tells LSIPR.

Showing 61 to 70 of 315 results

LSIPR